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Abstract
Background: Melanoma usually presents as an initial skin lesion without evidence of metastasis. A significant 
proportion of patients develop subsequent local, regional or distant metastasis, sometimes many years after the initial 
lesion was removed. The current most effective staging method to identify early regional metastasis is sentinel lymph 
node biopsy (SLNB), which is invasive, not without morbidity and, while improving staging, may not improve overall 
survival. Lymphatic density, Breslow's thickness and the presence or absence of lymphatic invasion combined has been 
proposed to be a prognostic index of metastasis, by Shields et al in a patient group.
Methods: Here we undertook a retrospective analysis of 102 malignant melanomas from patients with more than five 
years follow-up to evaluate the Shields' index and compare with existing indicators.
Results: The Shields' index accurately predicted outcome in 90% of patients with metastases and 84% without 
metastases. For these, the Shields index was more predictive than thickness or lymphatic density. Alternate lymphatic 
measurement (hot spot analysis) was also effective when combined into the Shields index in a cohort of 24 patients.
Conclusions: These results show the Shields index, a non-invasive analysis based on immunohistochemistry of 
lymphatics surrounding primary lesions that can accurately predict outcome, is a simple, useful prognostic tool in 
malignant melanoma.
Background
Melanoma, the most lethal form of skin cancer can be
highly metastatic. The most common site of metastatic
disease in melanoma is the regional lymph nodes indicat-
ing that metastatic spread usually occurs via the lym-
phatic system. Regional lymph node metastasis is
associated with a poor prognosis, with 10-year survival
rates of 35%[1]. The most widely used prognostic indica-
tor for survival is Breslow thickness, however, this is still
inaccurate for a significant number of patients[1]. A sig-
nificant proportion (15%) of patients with invasive thin
tumours (<1 mm), predicted to be low risk for spread, still
develop metastatic disease. There are currently no
accepted prognostic indicators to determine which of
these patients with thin melanoma will develop metasta-
sis. Similarly, a substantial proportion of patients with
thick melanoma will have long term survival (45% greater
than 10 years) and not develop regional or distant spread.
Under current clinical practice patients with confirmed
melanoma are staged according to Breslow thickness and
Clark's levels and in most centres are offered sentinel
lymph node biopsy (SLNB) (particularly if tumours are
thicker than 2 mm)[2]. After excision of the primary mel-
anoma, if the patient is node negative on clinical exami-
nation, or by SLNB, they are routinely followed up every
three months for five years. The sentinel lymph node
(SLN) is the first node draining the area of skin around
the primary malignant melanoma and is excised for his-
tological analysis. If the node is found to be positive
(SLN+ve) then regional lymph node clearance is usually
carried out, whereas patients who are SLNB negative
(SLN-ve) are followed up as usual, every three months for
up to five years. SLN+ve patients do not appear to benefit
in terms of overall survival from the subsequent lymph
node clearance surgery and there is no strong evidence to
show that it results in improvement in the rate of recur-
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rence or spread of the melanoma[2]. SLN-ve patients on
the other hand have a 15% 5-year mortality, compared
with 53% mortality for SLN+ve patients[3]. It is clear
therefore that SLNB is a useful indicator of likelihood of
recurrence[4], although it is has been proposed that it is
insensitive for 18-22% of patients (incorrectly predicts as
disease free)[5], and non-specific for 47% of patients
(incorrectly identifies them as likely to die from recur-
r e n c e )  i f  5 - y e a r  s u rv i v a l  s t a t i s t i c s  a r e  u s e d  a s  a n  e n d -
point[3]. In addition it requires significant theatre time,
and can be a cause of morbidity in a proportion of
patients, so there is still discussion in the literature of its
value and cost effectiveness[6]. It is thought that SLNB
predicts melanoma metastasis as melanoma cells that
gain access to the lymphatic system surrounding the pri-
mary lesion subsequently drain into the sentinel lymph
node, being seen as metastases, which can then seed sub-
sequent metastases to more distant lymph nodes[7].
Despite the uncertainty surrounding the mechanisms
underlying metastasis, there is a clear difference in lym-
phatic vessel density (LVD) surrounding primary malig-
nant melanomas, which then develop metastases,
compared with non-metastatic malignant melanomas
[8,9]. As a result, lymphatic density (number of lymphat-
ics per square mm bordering the melanoma) has been
suggested as a prognostic indicator for the progression
and spread of malignant melanoma[8-11]. This was
extended by Shields et al. (2004) to develop a prognostic
index in a small cohort of patients. This index considered
tumour thickness, peri-tumoral LVD and lymphatic inva-
sion, all of which contribute to metastasis, to generate a
more efficient predictor. The index was weighted to bias
factors that showed the greatest correlation with metasta-
sis. Therefore lymphatic vessel density was squared, as it
appeared to be the most important prognostic factor,
whilst lymphatic invasion was given a value of 2 if malig-
nant cells were seen to be present within LYVE-1 positive
vessels, and a value of 1 if none were found. Using this
Shields Index it was possible to differentiate tumours that
subsequently metastasised from those that did not, in a
small cohort of 21 patients, limiting its clinical value.
From such a small sampling it provides only limited anal-
ysis with regards to how robust the test is and the weight-
ing and value of each factor considered. In order to
consider the Shields Index for the clinical setting these
assessments are necessary. Our objective was to deter-
mine whether the Shields index is an effective predictor
of metastatic status in patients that were clinically metas-
tasis free upon excision of the primary melanoma. We
also set out to compare current predictive methodology
with the Shields index to determine the best method of
predicting metastatic outcome for patients.
Methods
The study conforms to the guidelines for Reporting Rec-
ommendations for Tumor Marker Prognostic Studies
(REMARK)[12]. Specific components of the REMARK
guidelines are identified in the text by numbers in dia-
mond brackets.
Patient details
The Frenchay Hospital Melanoma Registry contains orig-
inal samples taken at time of excision, information on
Breslow thickness, and metastatic outcome (i.e. whether
or not the patient went on to develop metastases), fol-
lowed up for a period of at least ten years on patients
treated by excision of melanomas from 1979. Melanoma
tissues were randomly selected from 102 patients from
the Registry, excluding any tumours that are only in situ
and then selecting participants under the following crite-
ria: clear of metastases at time of excision, with Breslow
thickness < 8 mm, with > 5-years of follow-up, and with
no signs of ulceration ?1,2?, with ethical approval from
North Bristol Research Ethics Committee (H7/0102/45).
Sections of melanomas, excised by wide local excision,
fixed in paraformaldehyde, cut into ~2 mm thick samples,
and paraffin embedded were used to calculate Breslow
thickness?3?. Samples were stored as paraffin embedded
blocks?4?. 57 patients did not develop clinically apparent
metastases within this follow-up period, described as
non-metastatic, 45 patients later developed either
regional or distant metastasis arising from the primary
tumour, described as metastatic?7?. 49 additional patient
samples were selected but not used for analysis. (5 had a
thickness > 8 mm, eight had indistinct borders of the mel-
anoma so LVD could not be calculated, 16 could not stain
with LYVE-1, five were lost due to poor preservation,
four were subsequently assessed to be melanoma in situ,
and eleven were lost to follow up ?10?.
18 additional patients had undergone SLNB at the
Royal Surrey Hospital, London. 8 were negative for signs
of metastasis at time of biopsy whereas 10 were positive.
All patients were negative for signs of metastasis at time
of primary tumour excision and were matched for
Breslow thickness.
Immunohistochemistry
Paraffin embedded sections were dewaxed re-hydrated,
and microwave antigen retrieval carried out in 0.01 M
sodium citrate, pH 6.0, 10 minutes at 800 W incubated in
3% hydrogen peroxide for 5 minutes, washed twice in
phosphate buffered saline (PBS (mM): NaCl, 137; KCl,
2.68; Na2HPO4, 10; KH2PO4, 1.76), incubated in 1.5%
normal horse serum in 1 × PBS for 30 minutes, and over-
night at 4°C in a humid chamber with polyclonal goat
anti-human LYVE-1 antibody; 15 μg/ml (AF2089, R&D
Systems, UK) or normal goat IgG (1-5000, Vector Labora-Emmett et al. BMC Cancer 2010, 10:208
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tories, Peterborough, UK), in non-immune block (Zymed
Laboratories, San Fransisco, USA). Slides were washed
twice in PBS/Tween, 0.05% v/v, (PBT) before blocking
and incubation with biotinylated horse anti-goat IgG sec-
ondary antibody (2 μg/ml BA-9500, Vector Laboratories,
Peterborough, UK) in blocking solution, in a humid
c h a m b e r  f o r  3 0  m i n u t e s .  S e c t i o n s  w e r e  w a s h e d  t w i c e
with 1 × PBT for 5 minutes before incubating for 30 min-
utes with Elite ABC Kit, (Vector Laboratories, Peterbor-
ough, UK) at room temperature. Sections were visualised
with diaminobenzidine (DAB, Vector Laboratories,
Peterborough, UK) and washed in distilled water, haema-
toxylin counterstained and DPX mounted.
Lymphatic vessel density
Sections were analysed independently by three experi-
enced researchers (DOB, KES and MSE). The researchers
were blinded to the status and reported Breslow thickness
of the melanoma, and the patients were anonymised to
the researchers. There was a high degree of reproducibil-
ity between the observers with >90% of samples having
the same number of lymphatics identified to within 2.
Lymphatic vessels were identified under a Nikon E400
microscope as structures positive for LYVE-1 staining.
Total epi-tumoural lymphatic vessel density (LVD) was
calculated using a × 40 objective, counting every lym-
phatic within a 350 μm border around the tumour edge.
Digital images were taken to form a composite image and
epi-tumoural area calculated using NIH Image J. Hot spot
analysis (identification of areas of subjectively deter-
mined high lymphatic density) of epi-tumoral LVD from
24 patients was assessed using a × 100 objective as previ-
ously described[10].
Shields Index ?5?
The Shields Index[8,9] (Box 1) was calculated from LVD,
Breslow thickness (thickness) and the presence or
absence of lymphatic vessel invasion (LVI). Lymphatic
vessel invasion was assessed using a × 40 objective and
defined as the presence of tumour cells within a LYVE-1
positive vessel within the primary tumour?11?.
Calculation of the Shields Index
Shields Index = (LVD2 × invasion) × (Breslow thickness) ?1?
LVD is the Total peri-tumoural lymphatic vessel density
Invasion = 2 if lymphatic invasion present, 1 otherwise
Statistical analysis?10?
AJCC stage, L VD, Breslow thickness, incidence of lym-
phatic invasion, and the Shields index were considered as
prognostic variables ?8?. Logistic regression models were
used to estimate associations between each of these vari-
ables in turn and subsequent occurrence of metastasis.
The discriminatory power of each variable was examined
using receiver operator characteristic (ROC) curves, and
areas under those curves (AUC). AUCs can be considered
the probability that the variable is at a higher level for
case compared with control, and can be compared
between variables using the test described by Hanley[13].
The sample size of 45 patients with metastases was antic-
ipated to allow a sensitivity of 90% to be estimated with
95% confidence interval of 76% to 96% ?9?.
There was no significant difference between metastatic
and non-metastatic patient groups in mean Breslow
t h i c k n e s s ,  p a t i e n t  a g e ,  o r  C l a r k s  L e v e l  ( T a b l e  1 )  ? 1 3 ? .
However, mean follow up time (time since excision of pri-
mary tumour) was significantly longer in the non meta-
static group, compared with metastatic group ?6?.
Logistic regression models were used to estimate asso-
ciations between metastasis and each of the following:
Breslow thickness, LVD, LVI and the Shields Index, The
prognostic power of each test was assessed using
Receiver Operator Characteristic Curves (ROC Curves)
and the area under the curve compared as described by
Hanley[13].
Results
Epi-tumoural lymphatic density and the shields index
Of the 102 patients selected from the Frenchay Hospital
Melanoma Registry, 45 were cases having developed
metastases within five years of follow-up, and 57 were
controls. There was strong evidence that metastasis was
associated with a higher mean LVD (Table 2, Figure 1A, p
= 0.001), a higher risk of lymphatic vessel invasion (Table
2, Figure 1B, p < 0.001), but no convincing evidence of an
association with Breslow thickness (Table 2, p = 0.15).
Table 1: Comparison of the metastatic and non-metastatic patient groups.
Age (years) Breslow Thickness (mm) Time Since Excision of Primary Lesion 
(months)
Clarks Level
Metastatic 57.23 ± 17.4 2.4 ± 1.6 53 ± 36 4.06 ± 0.26
Non-metastatic 55.63 ± 16.4 1.911 ± 1.4 92 ± 36 4.05 ± 0.37
There was no significant difference between metastatic and non-metastatic patient groups, in patient age (p > 0.05, one-way ANOVA, 
Bonferroni), Breslow thickness (p = 0.17 Mann Whitney U test), or Clarks level (p > 0.05, one-way ANOVA, Bonferroni). Mean follow up time 
(time since excision of primary tumour) was significantly longer in the non-metastatic group, compared with metastatic group (p < 0.0001 
unpaired t test). All results represent mean ± s.d.Emmett et al. BMC Cancer 2010, 10:208
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With regards to LVD, the mean densities in both cases
and controls are within the range of densities found in
normal dermis, which was described by Joory et al. as
falling between 0 to 25.1 mm-2 with a skewed right Pois-
son-like distribution with a mean 10.6 ± 0.67 mm-2 [9,14].
Similarly there was strong evidence of an association
between the Shields Index and subsequent metastasis
within five years (Table 2, Figure 1C, p < 0.001). For each
one log10 unit increase in the Shields index, there was an
almost ten-fold increase in the odds of metastases ?7,15?.
Discriminatory power of the different measures
Sensitivity specificity curves (figure 2), ROC curves and
AUCs indicate that the Shields Index achieves the great-
est discriminatory power, with AJCC staging performing
least well (Figure 3) in this group of patients who were
without lymph node or other metastasis at the time of
melanoma excision. The Shields Index achieved an AUC
of 0.82 (95% CI 0.73 to 0.90), significantly better than the
AUC of 0.70 for lymphatic vessel density (95% CI 0.60 to
0.80, p for comparison = 0.002). AJCC staging achieved
an AUC of 0.58 in this cohort while Breslow thickness
achieved an AUC of 0.58 in the 4,500 patients listed in the
Frenchay Hospital Melanoma Registry.
Adopting a cut-off of 2.1 for the Shields Index (Figure
4), 37 out of 45 patients with metastases within 5 years
exceed the cut-off, a sensitivity of 82%. Of the 57 patients
who did not develop metastases within five years, 46 fell
below the cut-off, a specificity of 81%. ?16,17?.
Sentinel Lymph Node Biopsy
In the 18 patients that had previously undergone SLNB,
epi-tumoural LVD was significantly higher in patients
who were positive for signs of SLN metastasis (8.2 ± 1.1
mm-2) compared to patients that were negative, (4.9 ± 1.8,
Figure 5A, p < 0.01, unpaired t-test). Lymphatic vessel
invasion was also increased in SLNB positive patients,
with 80% of SLNB positive patients positive for invasion
compared to only 37.5% of SLNB negative patients (Fig-
ure 5B, p = 0.145, Fisher's Exact Test). The mean Shields
Index value was significantly higher in SLNB positive
patients compared to negative patients (Figure 5C, p <
0.001, unpaired t test).
Hot Spot Analysis
A subset of 24 patients from the Frenchay Melanoma
Registry, were assessed for epi-tumoural LVD by both
total and hot spot analysis. Similar to total epi-tumoural
LVD assessment, hot spot analysis demonstrated an
increase in the number of lymphatics around metastatic
compared to non-metastatic tumours (Figure 6A, 7.75
vessels/mm2, metastatic, 5.28 vessels/mm2, non-meta-
static, p < 0.05, unpaired t-test). There was a high level of
correlation between both the total epi-tumoural LVD and
hot spot analysis (Figure 6B, p < 0.0001, Pearson, r2 =
0.50) and Shields Index and hot spot analysis (Figure 6C,
p < 0.01, Pearson, r2 = 0.30). The time taken to undertake
both the Shields Index and hot spot analysis were also
compared, with the Shields Index taking an average of
four times longer than hot spot analysis (Figure 6D, 19.0
± 1.1 minutes, Shields Index, 5.5 ± 0.6 minutes, hot spot
analysis, p < 0.0001, paired t-test. When the Shields Index
was calculated using total epi-tumoural LVD in this small
subset of patients, mean Shields Index for metastatic
patients was 2.5 ± 0.1 compared to 1.9 ± 0.1 for non-met-
astatic patients (Figure 6E, p < 0.01, unpaired t-test).
When the Shields Index was calculated in this same
patient cohort using hot spot analysis, there was still a
significant difference between the two groups, with a
mean Shields Index value of 2.3 ± 0.1 for metastatic
patients compared to 1.7 ± 0.1 for non-metastatic
patients (Figure 6E, p < 0.01, unpaired t-test). There was
no statistical significant difference between mean Shields
index calculated using the two methods (hot spot or
LVD). The Shields index calculated by hot spot analysis
gave a lower prognostic power than by LVD (AUC 0.75, p
< 0.05 compared with LVD Shields index).
Discussion
There is still some controversy over the management of
melanoma patients[6,7]. Sentinel lymph node biopsy is
used as a staging method for identification of non palpa-
Table 2: Associations between the Shields Index, the component measures, and subsequent metastases.
Metastasis at 5 yrs (n = 45) No metastasis at 5 yrs (n = 57) Odds ratio (95% CI) p
Mean lymphatic vessel density, 
vessels/mm2 (SD)
10.24 (5.54) 6.52 (3.82) 1.19 (1.08, 1.31) 0.001
Number with lymphatic vessel 
invasion (%)
38 (84) 26 (46) 6.47 (2.48, 16.90) <0.001
Mean Breslow thickness, mm (sd) 2.36 (1.55) 1.93 (1.37) 1.23 (0.93, 1.61) 0.15
Log shields index (sd) 2.43 (0.50) 1.77 (0.62) 9.86 (3.57, 27.24) <0.001
The odds ratios are for a one unit increase in LVD, Breslow thickness and the log10 Shields Index, and for the comparison between patients with 
and without lymphatic vessel invasion.Emmett et al. BMC Cancer 2010, 10:208
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ble regional lymph node metastasis [2,7]. However while
a positive lymph node finding may alter management of
the condition it does not improve overall survival of the
patient[2]. SNLB is costly, and invasive with >10% of
patients experiencing significant morbidities[4]. Yet it is
clearly more accurate than other prognostic factors for
patients node negative on clinical assessment, particu-
larly for those with intermediate thicknesses of mela-
noma. SLNB can clearly aid staging, trial choice, etc. It
does however, have a significant insensitivity (15-20%),
and a substantial non-specificity (45%), meaning that
many patients are put at unnecessary concern that they
have metastatic disease, and some have metastases that
are missed. The results we describe here provide a com-
plementary system to aid in prognostic determination of
melanoma. The Shields index is more specific and at least
equally sensitive compared to SLNB, and is accurate out-
side the safety net of SLNB patients. In the group
described here the Shields index was accurately able to
predict both metastasis derived from melanomas <2 mm,
and a lack of metastasis in thick melanomas (>4 mm).
?19?
There have been two primary methods for determining
lymphatic vessel density surrounding tumours. The
method primarily used here is an objective lymphatic
density counted from cross sections of LYVE-1 stained
lymphatic vessels per mm2 of section in a 350 μm (one
high powered field) border around the tumour. The alter-
native method involves counting vessels within three hot
spots of lymphatics surrounding the tumours[10]. There
was little difference in the accuracy of the methodology
when directly compared here, and although the hot spot
method had a slightly lower area under the curve value,
and was subjective, it was quicker. The Shields index
appears to be valid independent of the method of LVD
assessment. Although there is now an array of lymphatic
specific markers available, lymphatics were examined
herein through the sole use of LYVE-1. LYVE-1 is highly
specific and has been shown to be expressed almost
exclusively on the lymphatic endothelium [15]. Further-
more, direct comparisons of lymphatic vessel density cal-
culated with either LYVE-1 or other lymphatic markers,
has demonstrated that LYVE-1 offers the most accurate
assessment (unpublished data).
It is now clear that in animal models the incidence of
metastasis is increased in tumours expressing lymphatic
Figure 1 Mean epi-tumoural lymphatic vessel density and lym-
phatic vessel invasion. Lymphatic vessel density was significantly 
higher in tumours from patients that subsequently developed metas-
tases (metastatic), compared to non-metastatic tumours (p < 0.0001, 
unpaired t test). B) There were a greater percentage of tumours with 
signs of LVI in the metastatic patient group compared to the non-met-
astatic group (p < 0.001 Fisher's Exact Test). C) Shields Index values 
were calculated by combining peritumoural LD, LVI and Breslow thick-
ness. Mean Shields Index value was significantly higher in patients that 
subsequently developed metastases (metastatic), compared to non-
metastatic tumours (p < 0.0001, unpaired t test). Error bars represent 
standard error of the mean
Figure 2 Sensitivity and specificity curves for the different prog-
nostic factors. The sensitivity (i.e. the number of correctly predicted 
patients with metastatic spread) and specificity (i.e. the number of cor-
rectly predicted patients that did not develop metastases) were plot-
ted on the same axes as a representation of the predictive value of the 
prognostic test. The point at which the two lines intersect represents 
the optimal cut-off point for determining a positive or negative test re-
sult in order to achieve the best sensitivity and specificity for the test. 
A) Shields Index B) Breslow thickness for the 4500 patients included in 
the Frenchay Hospital Melanoma Registry C) Epi-tumoural LD D) AJCC 
stage.Emmett et al. BMC Cancer 2010, 10:208
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endothelial growth factors such as vascular endothelial
growth factor C (VEGF-C) [16]. Moreover, it has been
shown that areas of concentrated lymphatic endothelial
cell populations can stimulate the migration of melanoma
cells towards them resulting in melanoma growth to
areas of high lymphatic density through either directed
metastatic chemotaxis [17], and/or autologous chemot-
axis [18]. This has led to the hypothesis that tumours that
stimulate lymphangiogenesis, or can recognise areas of
high lymphatic density, will be more likely to metastasise
than tumours that do not.
The two mechanisms underlying increased lymphatic
density - chemotaxis and lymphangiogenesis - are also
now being understood at the molecular levels. Increased
VEGF-C production by melanomas can not only induce
lymphangiogenesis, but also increase lymph flow, thus
aiding fluid drainage from the tumour. This fluid drain-
age can serve to increase metastasis both by passively car-
rying tumour cells and by establishing autocrine
chemotactic gradients by autologously secreted heparin
binding growth factors such as VEGF-A or CCL21. Fur-
thermore, VEGF-C secreted by the tumour can result in
lymph node lymphangiogenesis [19], which results in a
more permissive environment for metastases from
micrometastases [20]. The second mechanism underlying
increased lymphatic density is metastatic chemotaxis.
Tumour cells that upregulate chemokine receptors for
molecules secreted by lymphatic endothelial cells recogn-
ise areas of lymphatic endothelial cell concentrations and
grow towards areas of high lymphatic density, or hot
spots[17,21]. These chemokines, such as CCL21 are used
by receptor expressing tumour cells (CCR7 for instance is
upregulated in metastatic but not non metastatic mela-
noma cells[22]) and provide a route out of the primary
melanoma to the lymph node. Thus increased lymphatic
density predicts the likelihood of SLNB positivity. It will
be interesting to determine whether combining SLNB
positivity with a high Shields value will increase the
already high sensitivity of each test, and whether a low
Shields value can be used to reduce SLNB in patients at
low risk.
Conclusions
We show that the use of the index described by Shields et
al. in 2004 is the most specific and sensitive method to
predict metastatic outcome (i.e. whether or not the
Figure 3 Receiver Operator Characteristic curves. A. Receiver Op-
erator Characteristic (ROC) curves were generated by plotting the sen-
sitivity (i.e. the proportion of times the test correctly predicts a patient 
as metastatic) against 1-specificity (i.e. 1-the proportion of times the 
test correctly predicts a patient as non-metastatic) as a measure of the 
predictive value for each test. Shields Index calculated by total LD and 
by hot spot, LD, Breslow thickness, Breslow thickness for the 4500 pa-
tients included in the Frenchay Hospital Melanoma Registry and AJCC 
staging. B. The area under the ROC curve (AUC) represents numerically 
the accuracy of the test. A prognostic indicator with 100% sensitivity 
and 100% specificity has an AUC of 1.0. The most accurate prognostic 
indicator is the Shields Index, followed by epi-tumoural LD, Breslow 
thickness and finally AJCC staging
Figure 4 Shields Index values scatterplot. The Shields Index values, 
for all 106 patients assessed, were plotted on a scatterplot to represent 
the spread in Shields Index values for the metastatic and non-meta-
static groups. The Shields Index (calculated from epi-tumoural LD, lym-
phatic vessel invasion and Breslow thickness). With a cut off point of 
2.10, 92 of the 106 samples are correctly predicted (86.8%) with only 14 
samples predicting incorrectly. A total of 5 patients that later devel-
oped metastases were predicted to be non-metastatic and 9 patients 
that have not yet developed metastases are predicted to do so.Emmett et al. BMC Cancer 2010, 10:208
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patient went on to develop metastases) in this group of
102 melanoma patients. This method is cheap, reproduc-
ible, and provides no additional invasive procedures from
the original primary excision of the tumour. These find-
ings suggest that selection of patients for SLNB could be
informed by the Shields' index values. Thus SLNB could
be targeted more towards those patients with thin mela-
nomas but high Shields index. It also suggests that staging
of metastatic melanoma should include this parameter, so
refining Breslow thickness [20].
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Figure 5 Comparison of epi-tumoural lymphatic vessel density, 
lymphovascular invasion, shields index and sentinel lymph node 
biopsy. Shields Index values were calculated on primary tumours from 
SNLB patients A) Mean epi-tumoural LD (p < 0.01, unpaired t test). B) 
Percentage of patients that were positive for LVI (p > 0.05, Fisher's Exact 
Test). C) Mean Shields Index values (p < 0.001, unpaired t test) for SLNB 
positive and negative patients. Error bars represent standard error of 
the mean.
Figure 6 Comparison of total lymphatic vessel density and hot 
spot analysis. Hot spot analysis and total LD were calculated. Hot spot 
analysis assessed lymphatic number by counting the number of im-
munohistochemically stained lymphatic vessels, in three regions with 
the highest LD, as assessed by eye, in a 100 μm border around the tu-
mour. A) Hot spots (p < 0.05, unpaired t test) in 12 patients that later 
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Total epi-tumoural LD and hot spot analysis were significantly correlat-
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